2025-11-14T17:01:26-06:00 2024-12-31 521186096 RUBINO AND COMPANY CHARTERED 6903 ROCKLEDGE DRIVE SUITE 300 BETHESDA MD 208171818 990 2024-01-01 815088460 CARING CROSS INC CARI 2409126874 910 CLOPPER ROAD 200S GAITHERSBURG MD 20878 MEGAN FORREST CHIEF OPERATING OFFICER 2409126874 2025-11-14 1 0 KAY VOLLANS CPA P01404047 3015643636 2024 2025-03-06 01:10:19Z BORO DROPULIC 910 CLOPPER ROAD 200S GAITHERSBURG MD 20878 6369884 0 X WWW.CARINGCROSS.ORG X 2017 MD FOCUSED UPON ACCELERATING THE DEVELOPMENT AND IMPLEMENTATION OF ADVANCED MEDICINES 15 14 33 14 0 0 2243444 3773205 15470452 1339248 36428 373031 0 880359 17750324 6365843 0 5529 0 0 2145844 3874391 0 0 0 2621360 6430770 4767204 10310690 12983120 -3944847 15530168 16467907 983565 5991534 14546603 10476373 X CARING CROSS IS FOCUSED UPON ACCELERATING THE DEVELOPMENT AND IMPLEMENTATION OF ADVANCED MEDICINES LIKE CAR-T CELL AND STEM CELL GENE THERAPIES. IN PARTNERSHIP WITH LIKE-MINDED STAKEHOLDERS, CARING CROSS DEVELOPS AND DEPLOYS TECHNOLOGIES, SYSTEMS AND THERAPEUTIC CANDIDATES THAT IMPROVE THE AFFORDABILITY AND ACCESSIBILITY OF THESE POTENTIALLY LIFE-SAVING THERAPIES FOR ALL PATIENTS IN NEED, EVERYWHERE. 0 0 5530229 5529 2219607 UNIVERSITY OF DELAWARE: NIIMBL RESEARCH DEVELOPMENT, AND TESTBEDS TO HELP THE NATION PREVENT, PREPARE FOR AND RESPOND TO CORONAVIRUS. 1365313 TOME BIOSCIENCES AND CARING CROSS INC. RESEARCH COLLABORATION 780267 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ON BEHALF OF ITS SAN FRANCISCO CAMPUS "UCSF": COMPLETE THE PHASE I IIA CLINICAL TRIAL DEVELOP A COMMERCIAL MANUFACTURING PROCESS AND DEVELOP A REGULATORY PATHWAY PLAN FOR DECENTRALIZED FDA APPROVAL OF THE ANTI-HIV DUOCAR-T CELL PRODUCT. 7675809 1 1 0 0 0 0 0 0 0 0 1 0 0 1 1 1 1 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 13 0 1 33 1 0 0 0 0 0 0 0 0 0 0 0 0 X 15 14 0 0 0 0 0 0 0 1 1 0 0 0 1 1 1 1 1 0 0 0 MD X NIKEL DAVIS 2409126874 910 CLOPPER ROAD 200S GAITHERSBURG MD 20878 BORO DROPULIC PHD MBA EXEC DIR., FOUNDER, PRESIDENT 40.00 X X 144119 0 7567 RIMAS ORENTAS PHD END 92024 SCIENTIFIC DIR., FOUNDER, SEC, PRES 40.00 X X 226676 0 23436 ZHONGYU ZHU CHIEF SCIENCE OFFICER 40.00 X 226058 0 0 MEGAN FORREST CHIEF OPERATING OFFICER 40.00 X 199365 0 22927 BEATRIX FERENCZ ASSOC. DIR. OF PROCESS DEVELOPMENT 40.00 X 157526 0 26845 IBE OPARAOCHA DIRECTOR OF PROCESS DEVELOPMENT 40.00 X 153078 0 7567 KARA ANLAUF SCIENCE RESOURCES AND COMMUNICATIONS 40.00 X 145555 0 5796 YING XIONG DIRECTOR OF CELL & GENE THERAPY 40.00 X 135903 0 21779 OXANA SLESSAREVA DIR. OF QUALITY SYSTEMS DEVELOPMENT 40.00 X 127203 0 6979 JENNIFER ADAIR PHD DIRECTOR 5.00 X 0 0 0 LINDSAY ANDROSKI JD DIRECTOR 5.00 X 0 0 0 NICANOR AUSTRIACO OP PHD STD DIRECTOR 5.00 X 0 0 0 DEUS BAZIRA DRPH MPH MBA DIRECTOR 5.00 X 0 0 0 MARK DYBUL MD DIRECTOR 5.00 X 0 0 0 JAMES KENNY MBA DIRECTOR 5.00 X 0 0 0 XIAOBIN LU PHD DIRECTOR 5.00 X 0 0 0 CRYSTAL MACKALL MD DIRECTOR 5.00 X 0 0 0 JULIE MAKANI MD PHD FRCP FTAAS DIRECTOR 5.00 X 0 0 0 MIKE MCCUNE MD PHD DIRECTOR 5.00 X 0 0 0 TOM ROSEDALE JD DIRECTOR 5.00 X 0 0 0 BARBARA SAVOLDO MD PHD DIRECTOR 5.00 X 0 0 0 NIRAV SHAH MD MSHP DIRECTOR 5.00 X 0 0 0 JOSHUA SPEIDEL PHD DIRECTOR 5.00 X 0 0 0 1515483 0 122896 15 0 1 0 VECTOR BIOMED INC 910 CLOPPER ROAD SUITE 200S GAITHERSBURG MD 20878 PRE-CLINICAL TESTING 708045 TJC LLC 3750 MIDDLEBURG ROAD UNION BRIDGE MD 21791 CONTRACTOR 148172 2 1772453 2000752 3773205 REVENUE FROM SERVICES 900099 1334248 1334248 NON-INVENTORY SALES 900099 5000 5000 1339248 375523 375523 880359 0 880359 880359 880359 1549 4041 -2492 -2492 -2492 6365843 2219607 0 373031 5529 5529 850148 840144 10004 2565619 2079628 485991 217342 178539 38803 241282 205455 35827 34167 34167 21123 21123 465532 215002 250530 413182 106598 306584 102811 6508 96303 1459318 183536 1275782 50460 24559 25901 40847 11099 29748 5696 315 5381 402580 395476 7104 11633 11633 LAB SUPPLIES & MATERIAL 3423421 3423421 10310690 7675809 2634881 0 134069 432133 12757302 5725401 1170906 420054 335587 172408 5357603 752818 1118943 4604785 100 0 13261 18426 0 5094700 15530168 16467907 983565 459429 0 5532105 983565 5991534 X 14533004 10462773 13599 13600 14546603 10476373 15530168 16467907 -3944847 -125383 0 X X 0 1 X 1 1 1 X 1144878 3355409 2978559 2243444 4075453 13797743 1144878 3355409 2978559 2243444 4075453 13797743 4238101 9559642 3 6183 36248 1255882 1298316 15096059 16507452 0.63330 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 5357603 752818 4604785 4604785 OPERATING LEASE RIGHT-OF-USE ASSET 5000239 FINANCE RIGHT-OF-USE ASSETS 94461 5094700 DEFERRED RENT 61974 OPERATING LEASE LIABILITY 5369699 FINANCE LEASE LIABILITY 100432 5532105 X 6368335 0 6368335 -2492 -2492 6365843 10313182 2492 2492 10310690 0 10310690 PART X, LINE 2: THE ORGANIZATION IS EXEMPT FROM FEDERAL INCOME TAXES, EXCEPT AS TO UNRELATED BUSINESS ACTIVITIES, UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE AND THE APPLICABLE INCOME TAX REGULATIONS OF THE STATE OF MARYLAND. THE ORGANIZATION IS NOT A PRIVATE FOUNDATION AND IS EXEMPT FROM TAXES ON INCOME OTHER THAN UNRELATED BUSINESS INCOME. NO PROVISION FOR INCOME TAXES IS REQUIRED FOR 2024. THE ORGANIZATION'S INCOME TAX RETURNS ARE SUBJECT TO REVIEW AND EXAMINATION BY FEDERAL AND STATE TAXING AUTHORITIES. THE ORGANIZATION IS NOT AWARE OF ANY ACTIVITIES THAT WOULD JEOPARDIZE ITS TAX-EXEMPT STATUS. INCOME TAX RETURNS FOR THE YEARS ENDED DECEMBER 31, 2023, 2022, AND 2021, ARE OPEN TO EXAMINATION BY THE TAXING JURISDICTIONS. PART XI, LINE 4B - OTHER ADJUSTMENTS: LOSS ON DISPOSAL -2,492. PART XII, LINE 2D - OTHER ADJUSTMENTS: LOSS ON DISPOSAL 2,492. 0 0 0 0 0 0 0 0 0 0 SUB-SAHARAN AFRICA 5529 0 1 0 0 0 0 0 0 0 X X 0 0 0 0 0 0 0 0 0 BORO DROPULIC PHD MBA EXEC DIR., FOUNDER, PRESIDENT 144119 0 0 0 0 0 0 0 7567 0 151686 0 0 0 RIMAS ORENTAS PHD END 92024 SCIENTIFIC DIR., FOUNDER, SEC, PRES 210592 0 0 0 16084 0 4534 0 18902 0 250112 0 0 0 ZHONGYU ZHU CHIEF SCIENCE OFFICER 226058 0 0 0 0 0 0 0 0 0 226058 0 0 0 MEGAN FORREST CHIEF OPERATING OFFICER 199365 0 0 0 0 0 317 0 22610 0 222292 0 0 0 BEATRIX FERENCZ ASSOC. DIR. OF PROCESS DEVELOPMENT 157526 0 0 0 0 0 3088 0 23757 0 184371 0 0 0 IBE OPARAOCHA DIRECTOR OF PROCESS DEVELOPMENT 153078 0 0 0 0 0 0 0 7567 0 160645 0 0 0 KARA ANLAUF SCIENCE RESOURCES AND COMMUNICATIONS 145555 0 0 0 0 0 2769 0 3027 0 151351 0 0 0 YING XIONG DIRECTOR OF CELL & GENE THERAPY 135903 0 0 0 0 0 2877 0 18902 0 157682 0 0 0 FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS REVIEWED BY MANAGEMENT AND MADE AVAILABLE TO ALL BOARD MEMBERS AFTER SUBMISSION. FORM 990, PART VI, SECTION B, LINE 12C CARING CROSS HAS A WRITTEN CONFLICT OF INTEREST POLICY THAT HAS BEEN GIVEN TO EACH BOARD MEMBER AND EMPLOYEE. EMPLOYEES AND BOARD MEMBERS ARE REQUIRED TO ANNUALLY READ AND SIGN A STATEMENT SIGNIFYING THAT THEY HAVE READ AND UNDERSTOOD THE POLICY. THE COPY OF THE SIGNED STATEMENT BY EACH EMPLOYEE IS MAINTAINED WITH THE EMPLOYMENT RECORDS. FORM 990, PART VI, SECTION B, LINE 15 CARING CROSS HAS A COMPENSATION COMMITTEE THAT CONSISTS OF BOARD MEMBERS AND AN INDEPENDENT DIRECTOR. THE COMMITTEE PERIODICALLY REVIEW THE ACHIEVEMENTS OF THE EXECUTIVE DIRECTOR AND EVALUATE WHETHER TO INCREASE COMPENSATION IN LIGHT OF THOSE ACHIEVEMENTS. FORM 990, PART VI, SECTION C, LINE 19 CARING CROSS INC.'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART XII, LINE 2C: THE PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR